ANI Pharmaceuticals Dividend

Dividend criteria checks 0/6

ANI Pharmaceuticals does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.3%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	US$0.74
Dividend yield forecast in 3Y	n/a

Recent dividend updates

No updates

Recent updates

These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

Feb 17

Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings

Nov 15

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if ANIP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ANIP's dividend payments have been increasing.

Dividend Yield vs Market

ANI Pharmaceuticals Dividend Yield vs Market

How does ANIP dividend yield compare to the market?
Segment	Dividend Yield
Company (ANIP)	n/a
Market Bottom 25% (US)	1.6%
Market Top 25% (US)	4.8%
Industry Average (Pharmaceuticals)	2.3%
Analyst forecast in 3 Years (ANIP)	n/a

Notable Dividend: Unable to evaluate ANIP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ANIP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate ANIP's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ANIP has not reported any payouts.

ANI Pharmaceuticals Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

ANI Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 10, 2024

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. Announces the Launch of Baclofen Oral Suspension

ANI Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

ANI Pharmaceuticals, Inc. Announces the Launch of Levofloxacin Oral Solution, USP

Consensus EPS estimates increase by 27%

Independent Director notifies of intention to sell stock

Price target increased by 7.5% to US$75.50

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

ANI Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

ANI Pharmaceuticals, Inc. to Report Second Half, 2023 Results on Feb 29, 2024

ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Indomethacin Oral Suspension, USP

Head of R&D notifies of intention to sell stock

Head of R&D notifies of intention to sell stock

Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings

Head of Rare Disease recently sold US$157k worth of stock

New minor risk - Earnings quality

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2023

New major risk - Revenue and earnings growth

ANI Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Head of R&D notifies of intention to sell stock

Ani Pharmaceuticals Announces Fda Approval and Commercial Availability of New 1-Ml Vial Size of Purified Cortrophin®? Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Arthritis Flares

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Head of R&D notifies of intention to sell stock

Ani Pharmaceuticals Announces the Fda Approval and Launch of Estradiol Gel, 0.1%

ANI Pharmaceuticals, Inc. Announces Board Changes

Head of R&D notifies of intention to sell stock

President recently sold US$3.3m worth of stock

President notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2023

ANI Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

New minor risk - Profitability

Head of R&D notifies of intention to sell stock

Price target increased by 12% to US$55.00

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $75.000033 million.

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Raises Revenue Guidance for Full Year 2023

Consensus EPS estimates fall by 42%, revenue upgraded

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 7.7% to US$46.60

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Levocarnitine Tablets USP

ANI Pharmaceuticals Announces the FDA Approval and Launch of Fluoxetine Oral Solution USP

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Trimethoprim Tablets USP

Consensus forecasts updated

High number of new directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ani Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Year 2022

We Think ANI Pharmaceuticals (NASDAQ:ANIP) Has A Fair Chunk Of Debt

ANI Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 09, 2022

ANI Pharmaceuticals, Inc. Appoints Krista Davis as Chief Human Resources Officer

ANI Pharmaceuticals Announces the Launch of Prochlorperazine Maleate Tablets USP

ANI Pharma launches generic Prochlorperazine maleate tablets

Key Executive notifies of intention to sell stock

Key Executive recently sold US$673k worth of stock

ANI Pharmaceuticals, Inc. Announces FDA Approval and Imminent Launch of Dexamethasone Tablets USP

ANI Pharmaceuticals' generic dexamethasone tablets get FDA approval

Consensus forecasts updated

ANI Pharmaceuticals, Inc. Reports Impairment Charge for the Second Quarter Ended June 30, 2022

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

ANI Pharmaceuticals Q2 2022 Earnings Preview

Ani Pharmaceuticals Announces the Launch of Acebutolol Hydrochloride Capsules USP

ANI Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 08, 2022

ANI Pharmaceuticals Appoints Meredith W. Cook as SVP, General Counsel and Corporate Secretary

ANI Pharmaceuticals Announces the FDA Approval and Imminent Launch of Fludrocortisone Acetate Tablets USP

ANI Pharmaceuticals, Inc. Provides Revenue Guidance for the Fiscal Year 2022

First quarter 2022 earnings: EPS misses analyst expectations

ANI Pharmaceuticals (NASDAQ:ANIP) Is Making Moderate Use Of Debt

Price target decreased to US$40.67